Enliven Therapeutics appoints Rick Fair as new CEO, shares down

Enliven Therapeutics

11/12/2025 14:43

** Shares of drug developer Enliven Therapeutics ELVN.O down 1.7% at $19.82

** Enliven appoints Rick Fair as chief executive officer, effective December 11

** Sam Kintz, co-founder and former CEO of Enliven, will assume a new role as Head of Pipeline, effective December 11

** Enliven plans to initiate a late-stage study of its experimental drug, ELVN-001, in patients with chronic myeloid leukemia in 2026

** Including session's moves, stock down 10.4% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))